Muse cells: the regenerative population we lose with age

Mesenchymal stem cells (MSCs) have disappointed for three decades, but not because the concept is flawed—rather because research has been using the wrong cellular subpopulation. Professor Mari Dezawa discovered Muse cells—multilineage-differentiating stress-enduring stem cells—entirely by accident when she left an MSC culture outside the incubator and found that some cells remained viable and adherent. Unlike conventional MSCs, Muse cells possess simultaneous capabilities that regenerative medicine has long pursued: targeted homing to injured tissue, pluripotent-like differentiation capacity, and the ability to evade immune rejection. Mitsubishi's Phase 2 randomized controlled trial in subacute stroke showed significant improvements across multiple recovery scales and functional markers. Most critically for longevity: this population naturally declines with age and in disease states—we are gradually losing our cellular repair squad's "A-team." MuseCell Innovations, which acquired the technology in 2024, is now moving beyond late-stage disease treatment into tissue integrity maintenance during healthy aging, with ten clinical trials in the pipeline and additional programs underway in orthopedics, cardiometabolic conditions, and preventive medicine.